Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials
- 1 December 1998
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 78 (11) , 1479-1487
- https://doi.org/10.1038/bjc.1998.710
Abstract
The purpose of this systematic study was to provide an up to date and reliable quantitative summary of the relative benefits of various types of chemotherapy (non-platinum vs platinum, single-agent vs combination and carboplatin vs cisplatin) in the treatment of advanced ovarian cancer. Also, to investigate whether well-defined patient subgroups benefit more or less from cisplatin- or carboplatin-based therapy. Meta-analyses were based on updated individual patient data from all available randomized controlled trials (published and unpublished), including 37 trials, 5667 patients and 4664 deaths. The results suggest that platinum-based chemotherapy is better than non-platinum therapy, show a trend in favour of platinum combinations over single-agent platinum, and suggest that cisplatin and carboplatin are equally effective. There is no good evidence that cisplatin is more or less effective than carboplatin in any particular subgroup of patients.Keywords
This publication has 26 references indexed in Scilit:
- Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study.Journal of Clinical Oncology, 1993
- Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.Journal of Clinical Oncology, 1992
- Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.Journal of Clinical Oncology, 1992
- A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancerBritish Journal of Cancer, 1992
- Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.Journal of Clinical Oncology, 1991
- Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinomaBJOG: An International Journal of Obstetrics and Gynaecology, 1990
- Randomized comparison of cyclophosphamide, doxorubicin and cisplatin (CAP) versus cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). A EORTC Gynecological Cancer Cooperative Group Study.1990
- Cyclophosphamide-Cisplatin Versus Cyclophosphamide-Carboplatin in Stage III-IV Ovarian Carcinoma: A Comparison of Equally Myelosuppressive RegimensJNCI Journal of the National Cancer Institute, 1989
- Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinomaCancer Chemotherapy and Pharmacology, 1989
- Cisplatin (P) versus Cyclophosphamide, Adriamycin and Cisplatin (CAP) for Stage III-IV Epithelial Ovarian Carcinoma: A Prospective Randomized TrialTumori Journal, 1988